2018
DOI: 10.1159/000487348
|View full text |Cite
|
Sign up to set email alerts
|

Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells

Abstract: Background/Aims: Ovarian cancer (OC) is the fifth leading cause of cancer-related death in women, and it is difficult to diagnose at an early stage. The purpose of this study was to explore the prognostic biological markers of OC. Methods: Univariate Cox regression analysis was used to identify genes related to OC prognosis from the Cancer Genome Atlas(TCGA) database. Immunohistochemistry was used to analyse the level of SPINK13 in OC and normal tissues. Cell proliferation, apoptosis and invasion were performe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
18
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(20 citation statements)
references
References 39 publications
2
18
0
Order By: Relevance
“…uPA, a serine protease with multiple function, acts as risk assessment and a possible treatment target in many cancers, [10,17,18] such as breast cancer, [9,19,20] pancreatic cancer, [21,22] prostate cancer, [23,24] and ovarian cancer. [2527] In particular, uPA can accelerate tumor metastasis and promote tumor angiogenesis by degrading extracellular matrix (ECM) and basement membranes, such as vimentin and fibronectin, involving in epithelial-mesenchymal transition (EMT). [27,28] Moreover, international guidelines (AGO, St. Gallen, ASCO) recommend the use of uPA and plasminogen activator inhibitor-1 (PAI-1) expression to better assess potential clinical benefit from adjuvant systemic treatment of breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…uPA, a serine protease with multiple function, acts as risk assessment and a possible treatment target in many cancers, [10,17,18] such as breast cancer, [9,19,20] pancreatic cancer, [21,22] prostate cancer, [23,24] and ovarian cancer. [2527] In particular, uPA can accelerate tumor metastasis and promote tumor angiogenesis by degrading extracellular matrix (ECM) and basement membranes, such as vimentin and fibronectin, involving in epithelial-mesenchymal transition (EMT). [27,28] Moreover, international guidelines (AGO, St. Gallen, ASCO) recommend the use of uPA and plasminogen activator inhibitor-1 (PAI-1) expression to better assess potential clinical benefit from adjuvant systemic treatment of breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…As a serine protease inhibitor, Hespintor inhibits the direct cleavage and activation of MMP by interacting with uPA, and its expression in non-tumor samples is significantly higher than that in hepatocellular carcinoma samples, especially in advanced hepatocellular carcinoma samples [5]. Except for our group's previous work, it has been reported that Hespintor can promote ovarian cancer metastasis after down-regulated expression of siRNA [10], which shows that Hespintor has strong antitumor activity. Based on the previous studies, the human hepatoma cell line MHCC97-H with high metastatic potential was selected to mimic advanced hepatocarcinoma's highly invasive characteristics [11].…”
Section: Discussionmentioning
confidence: 68%
“…Ovarian cancer cells in peritoneal cavity can invade the lined surface and grow above the peritoneal reflection in the pelvis [11]. Although surgery usually involves an en bloc resection of the ovarian tumors, reproductive organs, the sigmoid colon, and a primary bowel reanastomosis, micrometastasis of epithelial ovarian cancer cells via epithelial–mesenchymal–epithelial transition (EMT) did exist and accounted for many recurrence and death cases [12,13]. Therefore, in our study, we examined the role of CHTOP in epithelial ovarian cancer metastasis.…”
Section: Discussionmentioning
confidence: 99%